Advertisement
Screener

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Corbus Pharmaceuticals Holdings, Inc. Operating Cash Flow

Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Operating Cash Flow of -$55.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06

  • Corbus Pharmaceuticals Holdings, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$29.63M.
  • Corbus Pharmaceuticals Holdings, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$25.57M.
  • Corbus Pharmaceuticals Holdings, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$15.92M.
  • Corbus Pharmaceuticals Holdings, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$15.55M.
  • Corbus Pharmaceuticals Holdings, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$64.49M.
  • Corbus Pharmaceuticals Holdings, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$41.79M.
  • Corbus Pharmaceuticals Holdings, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$36.10M.
  • Corbus Pharmaceuticals Holdings, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$37.54M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 3 month as first filedNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 6 month as first filedNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 9 month as first filedNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 12 month as first filed
2026-06-30-$29.63M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$55.20M
10-Q · filed 2026-08-06
-$71.12M
derived: sum of 3 quarters · filed 2026-08-06
-$86.67M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$25.57M
10-Q · filed 2026-05-12
-$41.49M
derived: sum of 2 quarters · filed 2026-05-12
-$57.04M
derived: sum of 3 quarters · filed 2026-05-12
-$73.64M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$15.92M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09
-$31.47M
derived: sum of 2 quarters · filed 2026-03-09
-$48.07M
derived: sum of 3 quarters · filed 2026-08-06
-$64.49M
10-K · filed 2026-03-09
2025-09-30-$15.55M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
-$32.15M
derived: sum of 2 quarters · filed 2026-08-06
-$48.57M
10-Q · filed 2025-11-12
-$59.51M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$16.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$33.02M
10-Q · filed 2026-08-06
-$43.96M
derived: sum of 3 quarters · filed 2026-08-06
-$57.90M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$16.42M
10-Q · filed 2026-05-12
-$27.36M
derived: sum of 2 quarters · filed 2026-05-12
-$41.30M
derived: sum of 3 quarters · filed 2026-05-12
-$50.25M
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31-$10.94M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09
-$24.88M
derived: sum of 2 quarters · filed 2026-03-09
-$33.83M
derived: sum of 3 quarters · filed 2026-03-09
-$41.79M
10-K · filed 2026-03-09
2024-09-30-$13.94M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
-$22.89M
derived: sum of 2 quarters · filed 2025-11-12
-$30.85M
10-Q · filed 2025-11-12
-$36.86M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30-$8.94M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05
-$16.91M
10-Q · filed 2025-08-05
-$22.92M
derived: sum of 3 quarters · filed 2025-08-05
-$30.09M
derived: sum of 4 quarters · filed 2025-08-05
2024-03-31-$7.97M
10-Q · filed 2025-05-06
-$7.97M
10-Q · filed 2024-05-07
-$13.97M
derived: sum of 2 quarters · filed 2025-05-06
-$21.15M
derived: sum of 3 quarters · filed 2025-05-06
-$28.95M
derived: sum of 4 quarters · filed 2025-05-06
2023-12-31-$6.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11
-$13.18M
derived: sum of 2 quarters · filed 2025-03-11
-$20.99M
derived: sum of 3 quarters · filed 2025-03-11
-$36.10M
10-K · filed 2025-03-11
-$36.10M
10-K · filed 2024-03-12
2023-09-30-$7.18M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
-$14.98M
derived: sum of 2 quarters · filed 2024-11-07
-$30.09M
10-Q · filed 2024-11-07
-$30.09M
10-Q · filed 2023-11-07
-$37.55M
derived: sum of 4 quarters · filed 2024-11-07
2023-06-30-$7.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06
-$22.92M
10-Q · filed 2024-08-06
-$22.92M
10-Q · filed 2023-08-08
-$30.37M
derived: sum of 3 quarters · filed 2024-08-06
-$37.62M
derived: sum of 4 quarters · filed 2024-08-06
2023-03-31-$15.11M
10-Q · filed 2024-05-07
-$22.57M
derived: sum of 2 quarters · filed 2024-05-07
-$29.82M
derived: sum of 3 quarters · filed 2024-05-07
-$42.04M
derived: sum of 4 quarters · filed 2024-05-07
2022-12-31-$7.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12
-$14.70M
derived: sum of 2 quarters · filed 2024-03-12
-$26.93M
derived: sum of 3 quarters · filed 2024-03-12
-$37.54M
10-K · filed 2024-03-12
2022-09-30-$7.25M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07
-$19.47M
derived: sum of 2 quarters · filed 2023-11-07
-$30.09M
10-Q · filed 2023-11-07
-$39.79M
derived: sum of 4 quarters · filed 2023-11-07
2022-06-30-$12.23M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
-$22.84M
10-Q · filed 2023-08-08
-$32.55M
derived: sum of 3 quarters · filed 2023-08-08
-$31.69M
derived: sum of 4 quarters · filed 2023-08-08
2022-03-31-$10.62M
10-Q · filed 2023-05-09
-$20.32M
derived: sum of 2 quarters · filed 2023-05-09
-$19.46M
derived: sum of 3 quarters · filed 2023-05-09
-$36.99M
derived: sum of 4 quarters · filed 2023-05-09
2021-12-31-$9.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07
-$8.85M
derived: sum of 2 quarters · filed 2023-03-07
-$26.37M
derived: sum of 3 quarters · filed 2023-03-07
-$48.18M
10-K · filed 2023-03-07
2021-09-30$856.95K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
-$16.67M
derived: sum of 2 quarters · filed 2022-11-08
-$38.48M
10-Q · filed 2022-11-08
-$56.71M
derived: sum of 4 quarters · filed 2022-11-08
2021-06-30-$17.53M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
-$39.34M
10-Q · filed 2022-08-09
-$57.56M
derived: sum of 3 quarters · filed 2022-08-09
-$84.82M
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31-$21.81M
10-Q · filed 2022-05-10
-$40.03M
derived: sum of 2 quarters · filed 2022-05-10
-$67.29M
derived: sum of 3 quarters · filed 2022-05-10
-$93.89M
derived: sum of 4 quarters · filed 2022-05-10
2020-12-31-$18.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08
-$45.48M
derived: sum of 2 quarters · filed 2022-03-08
-$72.08M
derived: sum of 3 quarters · filed 2022-03-08
-$99.69M
10-K · filed 2022-03-08
2020-09-30-$27.25M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12
-$53.86M
derived: sum of 2 quarters · filed 2021-11-12
-$81.46M
10-Q · filed 2021-11-12
-$104.02M
derived: sum of 4 quarters · filed 2021-11-12
2020-06-30-$26.61M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
-$54.21M
10-Q · filed 2021-08-12
-$76.77M
derived: sum of 3 quarters · filed 2021-08-12
-$93.86M
derived: sum of 4 quarters · filed 2021-08-12
2020-03-31-$27.60M
10-Q · filed 2021-05-13
-$50.16M
derived: sum of 2 quarters · filed 2021-05-13
-$67.25M
derived: sum of 3 quarters · filed 2021-05-13
-$83.64M
derived: sum of 4 quarters · filed 2021-05-13
2019-12-31-$22.56M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15
-$39.65M
derived: sum of 2 quarters · filed 2021-03-15
-$56.04M
derived: sum of 3 quarters · filed 2021-03-15
-$45.72M
10-K · filed 2021-03-15
2019-09-30-$17.09M
derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-09
-$33.48M
derived: sum of 2 quarters · filed 2020-11-09
-$23.16M
10-Q · filed 2020-11-09
-$37.22M
derived: sum of 4 quarters · filed 2020-11-09
2019-06-30-$16.39M
derived: 10-Q/A 6 month − 10-Q 3 month · filed 2020-08-31
-$6.07M
10-Q/A · filed 2020-08-31
-$20.14M
derived: sum of 3 quarters · filed 2020-08-31
-$28.98M
derived: sum of 4 quarters · filed 2020-08-31
2019-03-31$10.32M
10-Q · filed 2020-05-11
-$3.75M
derived: sum of 2 quarters · filed 2020-05-11
-$12.59M
derived: sum of 3 quarters · filed 2020-05-11
-$18.15M
derived: sum of 4 quarters · filed 2020-05-11
2018-12-31-$14.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16
-$22.91M
derived: sum of 2 quarters · filed 2020-03-16
-$28.47M
derived: sum of 3 quarters · filed 2020-03-16
-$30.07M
10-K · filed 2020-03-16
2018-09-30-$8.85M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07
-$14.40M
derived: sum of 2 quarters · filed 2019-11-07
-$16.00M
10-Q · filed 2019-11-07
-$25.12M
derived: sum of 4 quarters · filed 2019-11-07
2018-06-30-$5.56M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08
-$7.16M
10-Q · filed 2019-08-08
-$16.27M
derived: sum of 3 quarters · filed 2019-08-08
-$22.60M
derived: sum of 4 quarters · filed 2019-08-08
2018-03-31-$1.60M
10-Q · filed 2019-05-09
-$10.71M
derived: sum of 2 quarters · filed 2019-05-09
-$17.05M
derived: sum of 3 quarters · filed 2019-05-09
2017-12-31-$9.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12
-$15.45M
derived: sum of 2 quarters · filed 2019-03-12
-$27.80M
10-K · filed 2019-03-12
2017-09-30-$6.33M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
-$18.68M
10-Q · filed 2018-11-08
2017-06-30-$12.35M
10-Q · filed 2018-08-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
Annexon, Inc. (ANNX)United States$0.147B-4.22
SPRUCE BIOSCIENCES, INC. (SPRB)United States$0.142B-2.89
Korro Bio, Inc. (KRRO)United States$0.141B-1.81
Atrium Therapeutics, Inc. (RNA)United States$0.140B
Curanex Pharmaceuticals Inc (CURX)United States$0.138B
TuHURA Biosciences, Inc./NV (HURA)United States$0.134B-4.88
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31
MEDICINOVA INC (MNOV)United States$0.130B-6.04
IMMUNIC, INC. (IMUX)United States$0.127B-1.88